Total Payments
$54,409
2024 Payments
$3,815
Companies
12
Transactions
37
Medicare Patients
24
Medicare Billing
$1,894
Payment Breakdown by Category
Research$49,855 (91.6%)
Other$4,160 (7.6%)
Food & Beverage$393.74 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $49,855 | 13 | 91.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,070 | 2 | 7.5% |
| Food and Beverage | $393.74 | 21 | 0.7% |
| Entertainment | $90.33 | 1 | 0.2% |
Payments by Type
Research
$49,855
13 transactions
General
$4,554
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $53,925 | 15 | $0 (2024) |
| ABBVIE INC. | $157.58 | 8 | $0 (2024) |
| Hitachi Healthcare Americas Corp. | $90.33 | 1 | $0 (2017) |
| Exeltis, USA Inc. | $71.97 | 3 | $0 (2024) |
| Daiichi Sankyo Inc. | $33.56 | 2 | $0 (2024) |
| Roche Diagnostics Corporation | $28.51 | 2 | $0 (2019) |
| Organon LLC | $25.84 | 1 | $0 (2022) |
| DEXCOM, INC. | $21.54 | 1 | $0 (2021) |
| Hologic Sales and Service, LLC | $15.34 | 1 | $0 (2023) |
| Kedrion Biopharma Inc. | $14.49 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,815 | 7 | PFIZER INC. ($3,700) |
| 2023 | $47,188 | 21 | PFIZER INC. ($47,025) |
| 2022 | $3,226 | 2 | PFIZER INC. ($3,200) |
| 2021 | $34.34 | 2 | DEXCOM, INC. ($21.54) |
| 2019 | $28.51 | 2 | Roche Diagnostics Corporation ($28.51) |
| 2017 | $116.93 | 3 | Hitachi Healthcare Americas Corp. ($90.33) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/30/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: Iron Deficiency Anemia | ||||||
| 10/15/2024 | Exeltis, USA Inc. | SLYND (Drug) | Food and Beverage | In-kind items and services | $24.70 | General |
| Category: CONTRACEPTIVE | ||||||
| 09/17/2024 | PFIZER INC. | ABRYSVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $3,700.00 | General |
| Category: VACCINES | ||||||
| 06/19/2024 | Exeltis, USA Inc. | SLYND (Drug) | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: CONTRACEPTIVE | ||||||
| 06/18/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: Iron Deficiency Anemia | ||||||
| 01/23/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/27/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $630.00 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 12/27/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $630.00 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 12/07/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $4,363.78 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 10/19/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $525.00 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 10/12/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $1,421.58 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 10/05/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $2,843.16 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 09/21/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $2,670.17 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 08/24/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 08/17/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $20,210.07 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 07/26/2023 | Exeltis, USA Inc. | SLYND (Drug) | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: Oral Contraceptive | ||||||
| 07/12/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: UROLOGY | ||||||
| 06/29/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: UROLOGY | ||||||
| 05/25/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $525.00 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 05/18/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $3,206.30 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 05/11/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $9,000.00 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 05/10/2023 | ABBVIE INC. | ORILISSA (Drug), LO LOESTRIN FE | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: WOMENS HEALTH | ||||||
| 04/07/2023 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $370.00 | General |
| 04/06/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $630.00 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $37,025 | 10 |
| PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $9,630 | 2 |
| RSV VACCINE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 12 | 12 | $2,721 | $879.96 |
| 2022 | 1 | 12 | 12 | $2,583 | $1,014 |
Total Patients
24
Total Services
24
Medicare Billing
$1,894
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 76830 | Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | Office | 2023 | 12 | 12 | $2,721 | $879.96 | 32.3% |
| 76830 | Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | Office | 2022 | 12 | 12 | $2,583 | $1,014 | 39.3% |
About Dr. Merlin Fausett, M.D
Dr. Merlin Fausett, M.D is a Maternal & Fetal Medicine healthcare provider based in Missoula, Montana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/11/2007. The National Provider Identifier (NPI) number assigned to this provider is 1659403038.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Merlin Fausett, M.D has received a total of $54,409 in payments from pharmaceutical and medical device companies, with $3,815 received in 2024. These payments were reported across 37 transactions from 12 companies. The most common payment nature is "" ($49,855).
As a Medicare-enrolled provider, Fausett has provided services to 24 Medicare beneficiaries, totaling 24 services with total Medicare billing of $1,894. Data is available for 2 years (2022–2023), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Maternal & Fetal Medicine
- Other Specialties Critical Care Medicine, Maternal & Fetal Medicine
- Location Missoula, MT
- Active Since 03/11/2007
- Last Updated 11/16/2025
- Taxonomy Code 207VM0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659403038
Products in Payments
- NURTEC ODT (Drug) $46,655
- ABRYSVO (Biological) $3,700
- BOTOX (Biological) $100.22
- Oasis MRI System (Device) $90.33
- SLYND (Drug) $71.97
- ORILISSA (Drug) $57.36
- INJECTAFER (Drug) $33.56
- RS Harmony Test Related Products (Device) $28.51
- NEXPLANON (Drug) $25.84
- DEXCOM G6 TRANSMITTER (Device) $21.54
- THINPREP 2000 PROCESSOR (Device) $15.34
- RHOGAM (Drug) $14.49
- Paragard (Device) $12.80
- Situate (Device) $12.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.